Marken Announces New Operations Center in Zurich
News Aug 19, 2016
Marken has announced the opening of their latest GDP-compliant operations center in Zurich, Switzerland, responding to increased demand from local pharmaceutical companies with growing clinical development programs. The new location is within close vicinity to the Zürich Airport (Kloten) freight terminal and is strategically located near major Swiss highways.
The facility, which operates 24/7/365, includes office and warehouse space with refrigerators and freezers available for temperature controlled packaging, full security and is connected to Marken’s global ‘Maestro’ operating system. The operation will be fully staffed, capable of collecting and shipping clinical drug product from the Zurich gateway to anywhere in the world. The facility also conforms to the Swiss Minergie (green) standard, a registered quality label for new and refurbished low-energy-consumption buildings.
Wes Wheeler, Chief Executive Officer for Marken, commented, “Marken has built a global logistics network specifically designed to meet the needs of the global pharmaceutical industry. Our newest site in Zurich replaces our smaller office with expanded capabilities so that we can be ready for the increased clinical logistics demands from our clients. We have also set the standard for GDP compliance – especially in Europe – and will certify the operations according to our own ‘Gold Book’ standard.”
Wheeler concluded: “We are the only 100%-dedicated, patient centric supply chain organization in the life sciences industry. We will continue to expand our global footprint to meet the increasingly demanding requirements of our clients.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018